

Connecticut HB 6669

OGSIVEO® (Nirogacestat)

SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany (“SpringWorks”) provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects IBSA’s Wholesale Acquisition Costs (“WAC”) for their product: **OGSIVEO®**. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for OGSIVEO®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
OGSIVEO®	82448-0100-14	Oral Tablet 100 MG	\$7,746.58
OGSIVEO®	82448-0150-14	Oral Tablet 150 MG	\$7,746.58

Generic versions of **OGSIVEO®** are not currently available. Information on variation efficacy of the drug marketed to different racial and ethnic groups is not currently available.

For more information on the price disclosure requirements, please contact the Connecticut State Board of Pharmacy at:

State Board of Pharmacy
450 Columbus Blvd.
Hartford, CT 06103

Ph. (860) 713-6070 | Fax: (860) 706-1242 | Website: <https://portal.ct.gov/DCP/Drug-Control-Division/Commission-of-Pharmacy/The-Commission-of-Pharmacy>

OGSIVEO® is a registered trademark of SpringWorks, a healthcare company of Merck KGaA Darmstadt, Germany
Copyright© 2026 SpringWorks all rights reserved.
01/05/2026